Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

Karpe KM, Talaulikar GS, Walters GD.

Cochrane Database Syst Rev. 2017 Jul 21;7:CD006750. doi: 10.1002/14651858.CD006750.pub2. Review.

PMID:
28730648
2.

Contextualising renal patient routines: Everyday space-time contexts, health service access, and wellbeing.

McQuoid J, Jowsey T, Talaulikar G.

Soc Sci Med. 2017 Jun;183:142-150. doi: 10.1016/j.socscimed.2017.04.043. Epub 2017 Apr 27.

PMID:
28482275
3.

Sleep apnea prevalence in chronic kidney disease - association with total body water and symptoms.

Huang HC, Walters G, Talaulikar G, Figurski D, Carroll A, Hurwitz M, Karpe K, Singer R.

BMC Nephrol. 2017 Apr 4;18(1):125. doi: 10.1186/s12882-017-0544-3.

4.

A Trial of Extending Hemodialysis Hours and Quality of Life.

Jardine MJ, Zuo L, Gray NA, de Zoysa JR, Chan CT, Gallagher MP, Monaghan H, Grieve SM, Puranik R, Lin H, Eris JM, Zhang L, Xu J, Howard K, Lo S, Cass A, Perkovic V; ACTIVE Dialysis Steering Committee; Paul.

J Am Soc Nephrol. 2017 Jun;28(6):1898-1911. doi: 10.1681/ASN.2015111225. Epub 2017 Feb 1.

5.

Regional citrate anticoagulation in hemodialysis: an observational study of safety, efficacy, and effect on calcium balance during routine care.

Singer RF, Williams O, Mercado C, Chen B, Talaulikar G, Walters G, Roberts DM.

Can J Kidney Health Dis. 2016 Apr 20;3:22. doi: 10.1186/s40697-016-0113-x. eCollection 2016.

6.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

7.

Allograft adenovirus nephritis.

Rady K, Walters G, Brown M, Talaulikar G.

Clin Kidney J. 2014 Jun;7(3):289-92. doi: 10.1093/ckj/sfu020. Epub 2014 Mar 23.

8.

Multiple biomarkers including cardiac troponins T and I measured by high-sensitivity assays, as predictors of long-term mortality in patients with chronic renal failure who underwent dialysis.

Hickman PE, McGill D, Potter JM, Koerbin G, Apple FS, Talaulikar G.

Am J Cardiol. 2015 Jun 1;115(11):1601-6. doi: 10.1016/j.amjcard.2015.02.066. Epub 2015 Mar 14.

PMID:
25851798
9.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

10.

Diastolic function is a strong predictor of mortality in patients with chronic kidney disease.

Farshid A, Pathak R, Shadbolt B, Arnolda L, Talaulikar G.

BMC Nephrol. 2013 Dec 23;14:280. doi: 10.1186/1471-2369-14-280.

11.

KHA-CARI Guideline: vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts.

Polkinghorne KR, Chin GK, MacGinley RJ, Owen AR, Russell C, Talaulikar GS, Vale E, Lopez-Vargas PA.

Nephrology (Carlton). 2013 Nov;18(11):701-5. doi: 10.1111/nep.12132. No abstract available. Erratum in: Nephrology (Carlton). 2014 Jan;19(1):64.

PMID:
23855977
12.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

13.

Safety and predictors of complications of renal biopsy in the outpatient setting.

Jiang SH, Karpe KM, Talaulikar GS.

Clin Nephrol. 2011 Dec;76(6):464-9.

PMID:
22105449
14.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators.

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

15.

Resolution of renal failure 1 month after onset through angioplasty of renal artery stenosis.

Jiang SH, Ussher SH, Lalloo S, Talaulikar GS.

Ren Fail. 2011;33(5):548-50. doi: 10.3109/0886022X.2011.569103. Epub 2011 Apr 4.

PMID:
21463178
16.

Peritoneal dialysis-related peritonitis due to Mycobacterium smegmatis.

Jiang SH, Senanayake S, Talaulikar GS.

Perit Dial Int. 2011 Mar-Apr;31(2):215-6. doi: 10.3747/pdi.2010.00074. No abstract available.

PMID:
21427257
17.

Antibiotic stability in commercial peritoneal dialysis solutions: influence of formulation, storage and duration.

Roberts DM, Fernando G, Singer RF, Kennedy KJ, Lawrence M, Talaulikar G.

Nephrol Dial Transplant. 2011 Oct;26(10):3344-9. doi: 10.1093/ndt/gfr005. Epub 2011 Feb 15.

PMID:
21324977
18.

Validation of the measurement of haemodialysis access flow using a haemoglobin dilution test.

Jiang SH, Clayton PA, Maguire A, Talaulikar GS.

Blood Purif. 2011;32(1):48-52. doi: 10.1159/000323554. Epub 2011 Feb 11.

PMID:
21311186
19.

Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis.

Yew CT, Talaulikar GS, Falk MC, Clayton P, D'Rozario J, Brown M.

Nephrology (Carlton). 2010 Apr;15(3):377. doi: 10.1111/j.1440-1797.2009.01183.x. No abstract available.

PMID:
20470310
20.

Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure.

McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE.

Clin Chim Acta. 2010 Jul 4;411(13-14):936-9. doi: 10.1016/j.cca.2010.03.004. Epub 2010 Mar 16.

PMID:
20298685

Supplemental Content

Loading ...
Support Center